Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Complete Remission in Patients With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab - A Multicenter, Prospective Observational Cohort Study in Canada, Italy, and Israel

NCT05192863 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05192863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05192863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Complete Remission in Patients With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab - A Multicenter, Prospective Observational Cohort Study in Canada, Italy, and Israel
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
March 20, 2023
Completion date
October 31, 2025
Enrollment
72 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease